menu
    • menu
    [{"orgOrder":0,"company":"Arecor","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2025","type":"Agreement","leadProduct":"Nimacimab","moa":"||Cannabinoid CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Skye Bioscience","highestDevelopmentStatusID":"8","companyTruncated":"Arecor \/ Skye Bioscience"},{"orgOrder":0,"company":"Arecor","sponsor":"TRx Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2024","type":"Collaboration","leadProduct":"Semaglutide","moa":"Glucagon-like peptide 1 receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arecor \/ TRx Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Arecor \/ TRx Biosciences"},{"orgOrder":0,"company":"Arecor","sponsor":"Tetris Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Acquisition","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Arecor","highestDevelopmentStatusID":"15","companyTruncated":"Arecor \/ Arecor"},{"orgOrder":0,"company":"Arecor","sponsor":"Tetris Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Agreement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Arecor","highestDevelopmentStatusID":"15","companyTruncated":"Arecor \/ Arecor"},{"orgOrder":0,"company":"Tetris Pharma","sponsor":"Xeris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide, Unconjugated","year":"2021","type":"Licensing Agreement","leadProduct":"Glucagon","moa":"Glucagon receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Tetris Pharma","amount2":0.070000000000000007,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Endocrinology","amount2New":0.070000000000000007,"dosageForm":"Injection","sponsorNew":"Tetris Pharma \/ Tetris Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Tetris Pharma \/ Tetris Pharma"},{"orgOrder":0,"company":"Arecor","sponsor":"Medtronic Plc","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Preclinical","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Implant","sponsorNew":"Arecor \/ Medtronic Plc","highestDevelopmentStatusID":"4","companyTruncated":"Arecor \/ Medtronic Plc"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"AT247","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"AT278","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"AT278","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2019","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"INSR||Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2020","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ultra Rapid Acting Insulin Aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Ultra Rapid Acting Insulin Aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Fast Acting Insulin Aspart","moa":"||Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"UNITED KINGDOM","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Adalimumab","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Arecor \/ Undisclosed"},{"orgOrder":0,"company":"Arecor","sponsor":"Sequel Med Tech LLC","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Hormone","year":"2025","type":"Agreement","leadProduct":"Insulin aspart","moa":"Insulin receptor","graph1":"Endocrinology","graph2":"Phase I","graph3":"Arecor","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Arecor \/ Sequel Med Tech LLC","highestDevelopmentStatusID":"6","companyTruncated":"Arecor \/ Sequel Med Tech LLC"}]

    Find Clinical Drug Pipeline Developments & Deals by Arecor

    Menu

    Arecor

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin aspart

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Sequel Med Tech LLC

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Arecor Announces Co-development Agreement with Insulin Pump Device Company for AT278

                            Details : AT278 is the only ultra-concentrated and ultra-rapid acting insulin in development designed to enable the next generation of longer-wear and miniaturised automated insulin delivery (AID) systems

                            Product Name : AT278

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            September 25, 2025

                            Lead Product(s) : Insulin aspart

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Sequel Med Tech LLC

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nimacimab,Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Skye Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Skye Bioscience Partners with Arecor to Improve Obesity Drug Nimacimab

                            Details : Under the agreement, Skye will fund Arecor’s development activities with the option to license rights to the new formulation of nimacimab and to further develop & commercialize the product.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            May 19, 2025

                            Lead Product(s) : Nimacimab,Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Skye Bioscience

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin aspart

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            At278 Insulin Shows Superiority in Phase I Trial for Type 2 Diabetes

                            Details : AT278 is an ultra-concentrated, ultra-rapid acting, novel formulation of insulin that accelerates the absorption of insulin post injection. It is being evaluated for the treatment of type 2 diabetics.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            May 20, 2024

                            Lead Product(s) : Insulin aspart

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : Medtronic Plc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Arecor and Medtronic Collaborate to Develop Novel Thermostable Insulin for Pump Delivery

                            Details : The collaboration aims to develop a novel, high concentration, thermostable insulin for use by Medtronic’s Diabetes business in a next-generation implantable pump.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Undisclosed

                            May 09, 2024

                            Lead Product(s) : Insulin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : Medtronic Plc

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Study Phase : Preclinical

                            Sponsor : TRx Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Arecor and TRX Biosciences Establish Collaboration for Oral GLP-1 Development

                            Details : A collaboration will enhance oral semaglutide's bioavailability using novel lipid technology for diabetes and obesity treatment.

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            March 12, 2024

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Preclinical

                            Sponsor : TRx Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AT278

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study

                            Details : AT278 is a Hormone drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            March 03, 2023

                            Lead Product(s) : AT278

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Recipient : Tetris Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Tetris Pharma Signs Service Agreement With Syneos Health

                            Details : Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycaemia.

                            Product Name : Ogluo

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            December 12, 2022

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Recipient : Tetris Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ultra Rapid Acting Insulin Aspart

                            Therapeutic Area : Endocrinology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Headline Results From Phase I Clinical Trial Of Ultra-rapid Acting Insulin Candidate AT247 Demonstrate Signifi...

                            Details : AT247 (ultra rapid acting prandial insulin aspart) has the potential to significantly improve blood glucose control when delivered via insulin pump and is an important step in enabling the development of a fully closed loop/artificial pancreas system for...

                            Product Name : Undisclosed

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Inapplicable

                            October 11, 2022

                            Lead Product(s) : Ultra Rapid Acting Insulin Aspart

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Arecor Granted European Patents Protecting Proprietary Formulations of High Concentration Humira® Biosimilar

                            Details : Humira approved as 50 mg/mL adalimumab product comprising citrate as formulation ingredient. An product was subsequently launched by AbbVie with high adalimumab concentration in absence of citrate, providing greater patient convenience due to the lower i...

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 09, 2022

                            Lead Product(s) : Adalimumab

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed

                            Arecor

                            United Kingdom arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved FDF

                            Recipient : Tetris Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Xeris’ Commercialization Partner for Ogluo, Tetris Pharma Ltd, to Be Acquired by Arecor Therapeutics

                            Details : Under the terms of the proposed acquisition, Arecor Therapeutics has agreed to acquire Tetris Pharma and will continue to commercialize Ogluo in the UK and EEA. Gvoke® (US) /Ogluo® (EU), the first prescription, ready-to-use, pre-mixed, pre-measured glu...

                            Product Name : Ogluo

                            Product Type : Peptide, Unconjugated

                            Upfront Cash : Undisclosed

                            August 01, 2022

                            Lead Product(s) : Glucagon

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved FDF

                            Recipient : Tetris Pharma

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth